Avelos Therapeutics Inc. has divulged new sulfur or selenium-containing compounds acting as DNA polymerase θ (POLθ; POLQ) inhibitors potentially useful for the treatment of cancer.

A Purdue Research Foundation patent details the discovery of 5/5-5/6 bisaryl compounds acting as mitogen-activated protein kinase kinase kinase 7 (MAP3K7; TAK1) inhibitors reported to be useful for the treatment of multiple myeloma and inflammatory disorders.

Beone Medicines I GmbH and Beone Pharmaceutical (Suzhou) Co. Ltd. have identified new macrocyclic GTPase KRAS inhibitors potentially useful for the treatment of cancer.

Affirma Biotech SL has disclosed new programmed cell death 1 (PDCD1; PD-1; CD279)/PD-1 ligand 1 (PD-L1; CD274) interaction inhibitors potentially useful for the treatment of cancer, bacterial, fungal and viral infections.

Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1 (HCN1) and HCN2 blockers potentially useful for the treatment of pain, tinnitus, neurological and mood disorders.

Ewha Womans University and Gachon University have discovered new pyrazinocarbazole derivatives acting as transcriptional coactivator YAP1/transcriptional enhancer factor (TEAD) interaction inhibitors potentially useful for the treatment of colorectal cancer.

Leonabio Inc. has patented new pannexin-1 (PANX1; MRS1) inhibitors described as useful for the treatment of inflammatory disorders, epilepsy and pain.

Blossomhill Therapeutics Inc. has identified new macrocyclic compounds potentially useful for the treatment of cancer.

A Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. patent describes new probable global transcription activator SNF2L2 (SMARCA2; BAF190B; SNF2-α) inhibitors potentially useful for the treatment of cancer.

Forward Therapeutics Inc. has identified new TNF-α inhibitors potentially useful for the treatment of inflammatory disorders and autoimmune diseases.